Breaking Finance News

Integra Lifesciences Holdings Corp (NASDAQ:IART) has been downgraded to Sell in a report by Zacks Investment Research today.

Having a price of $81.98, Integra Lifesciences Holdings Corp (NASDAQ:IART) traded 1.31% higher on the day. With the last stock price up 7.25% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. The company has recorded a 50-day moving average of $85.40 and a 200-day moving average of $77.43. 438,840 shares of the stock were exchanged, up from an avg. volume of 289,592

Zacks Investment Research has downgraded Integra Lifesciences Holdings Corp (NASDAQ:IART) to Sell in a statement released on 10/07/2016.

Performance Chart

Integra Lifesciences Holdings Corp (NASDAQ:IART)

With a total market value of $0, Integra Lifesciences Holdings Corp has price-earnings ratio of 343.18 with a one year low of $54.75 and a one year high of $88.86 .

A total of 11 brokers have reported on the stock. 6 equity analysts rating the company a strong buy, 3 brokerages rating the company a buy, six brokers rating the stock a hold, 0 equity analysts rating the company a underperform, and finally 0 firms rating the company a sell with a 12-month price target of $80.27.

More About Integra Lifesciences Holdings Corp (NASDAQ:IART)

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing and marketing of surgical implants and medical instruments. Its products are used in neurosurgery, extremity reconstruction, orthopedics and general surgery. Its segments include Specialty Surgical Solutions, which offers products, including specialty surgical instrumentation for a range of specialties. Its product category includes products and solutions for dural repair, precision tools and instruments, tissue ablation and neuro critical care, including product portfolios used in neurosurgery operation suites and critical care units, and Orthopedics and Tissue Technologies, which offers products of a combination of differentiated regenerative technology products for soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement hardware products for both upper extremities and lower extremities.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *